Follow‐up and data collection
nausea, dyspnea, fatigue, diarrhea, pain, constipation, insomnia, Toxicity, Cancer
APPETITE LOSS, ADVERSE EVENTS, CANCER
All enrolled patients were evaluated for two chemotherapy cycles. The EORTC QLQ C30 questionnaire was completed independently by the enrolled patients prior to the first, second, and third cycles of chemotherapy. The scale consisted of 30 items, including five functional dimensions (physical function, role function, cognitive function, emotional function, and social function), nine symptom dimensions (fatigue, pain, nausea and vomiting, dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties), and one dimension of overall quality of life.The National Cancer Institute Common Toxicity Criteria (version 4.0) was used for the evaluation of adverse events.